Full Press Release Details
Belite Bio Announces
PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
22, 2024 - Belite Bio, Inc (NASDAQ: BLTE) ("Belite Bio" or the "Company"), a clinical-stage biopharmaceutical
drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet
medical needs, today announces its submission to the Pharmaceuticals and Medical Devices Agency (PMDA) to initiate a clinical trial of
Tinlarebant in adolescent STGD1 in Japan ("DRAGON II").
trial is a combination of Phase 1b open-label study to evaluate the pharmacokinetics and pharmacodynamics of Tinlarebant in Japanese
adolescent STGD1 subjects and a Phase 2/3, global, multicenter, double-masked, placebo-controlled, randomized study designed to
evaluate the efficacy, safety and tolerability of Tinlarebant in adolescent STGD1 subjects. Approximately 60 subjects, aged 12 to 20
years old, including approximately 10 Japanese subjects, are targeted for enrollment in the Phase 2/3 portion of the trial with a
1:1 randomization (tinlarebant:placebo). The data from Japanese subjects is intended to facilitate future NDA applications in
Tinlarebant (a/k/a LBS-008)
is a novel oral therapy that is intended to reduce the accumulation of vitamin A-based toxins (known as bisretinoids) that cause retinal
disease in STGD1 and also contribute to disease progression in GA, or advanced Dry AMD. Bisretinoids are by-products of the visual cycle,
which is dependent on the supply of vitamin A (retinol) to the eye. Tinlarebant works by reducing and maintaining levels of serum retinol
binding protein 4 (RBP4), the sole carrier protein for retinol transport from the liver to the eye. By modulating the amount of retinol
entering the eye, Tinlarebant reduces the formation of bisretinoids. Tinlarebant has been granted Fast Track Designation and Rare Pediatric
Disease designation in the U.S., and Orphan Drug Designation in the U.S., Europe, and Japan for the treatment of STGD1.
is the most common inherited retinal dystrophy (causing blurring or loss of central vision) in both adults and children. The disease
is caused by mutations in a retina-specific gene (ABCA4), which results in progressive accumulation of bisretinoids leading to retinal
cell death and progressive loss of central vision. The fluorescent properties of bisretinoids and the development of retinal imaging
systems have helped ophthalmologists identify and monitor disease progression. Currently, there are no FDA approved treatments for STGD1.
STGD1 and GA, or advanced Dry AMD, share a similar pathophysiology, which is characterized by the excessive accumulation of bisretinoids,
retinal cell death, and progressive loss of vision. Vision loss occurs slowly, despite peripheral expansion of "dead retina,"
until the disease reaches the center of the eye (the macula). Therefore, Belite Bio is evaluating safety and efficacy of Tinlarebant
in GA patients in a 2-year Phase 3 study (PHOENIX).
in advanced Dry Age-related Macular Degeneration (Dry AMD)
Dry AMD is a leading cause of vision
loss in older adults. Geographic Atrophy, or GA, is the advanced stage of AMD. Currently, there are no FDA approved orally administered
treatments for GA and no FDA approved therapies for the other stages of Dry AMD other than GA. There are an estimated 20 million AMD
patients in the U.S. and over 196 million patients worldwide with an estimated global direct healthcare cost of US$255 billion.
clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye
diseases which have significant unmet medical needs such as (i) atrophic age-related macular degeneration (AMD), commonly known as Geographic
Atrophy (GA) in advanced dry AMD, and (ii) autosomal recessive Stargardt disease type 1, or STGD1, in addition to specific metabolic
Important Cautions Regarding Forward
This press release contains
forward-looking statements about future expectations and plans, as well as other statements regarding matters that are not historical
facts. These statements include but are not limited to statements regarding the potential implications of clinical data for patients,
and Belite Bio's advancement of, and anticipated preclinical activities, clinical development, regulatory milestones, and commercialization
of its product candidates, and any other statements containing the words "expect", "hope" and similar expressions.
Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors,
including but not limited to Belite Bio's ability to demonstrate the safety and efficacy of its drug candidates; the clinical results
for its drug candidates, which may not support further development or regulatory approval; the timing to complete relevant clinical trials
and/or to receive the interim/final data of such clinical trials; the content and timing of decisions made by the relevant regulatory
authorities regarding regulatory approval of Belite Bio's drug candidates; the potential efficacy of Tinlarebant, as well as those
risks more fully discussed in the "Risk Factors" section in Belite Bio's filings with the U.S. Securities and Exchange
Commission. All forward-looking statements are based on information currently available to Belite Bio, and Belite Bio undertakes no obligation
to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except
as may be required by law.
Jennifer Wu /ir@belitebio.com
Julie Fallon / belite@argotpartners.com